Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
Would you switch to a TNF-I if patient developed squamous cell skin cancer on Orencia after failure of MTX for seropositive RA?
patient had no prior TNF-I exposure and was not on MTX while receiving Orencia
Related Questions
Do you feel comfortable using Jak inhibitors in patients with a strong family history of CAD, but no other risk factors?
What is your approach to work up for patients referred for early onset osteoarthritis?
How do you manage pleuroparenchymal fibroelastosis in a patient with seronegative RA that is progressing on Rituxan and DMARD therapy?
When considering biologic therapy after failure of MTX or triple therapy, do you consider using Abatacept as a first line biologic?
How do you help patients understand the difference between prolonged morning stiffness and pain?
Would you consider using a JAK inhibitor for a patient with RA associated scleritis?
What is the maximum dose of leucovorin that you use with methotrexate?
Would you add abatacept to treat active inflammatory arthritis in a patient with history of RA-ILD who is already taking mycophenolate?
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
When do you recommend initiation of targeted therapies in active RA with history of malignancy?